KLIFO has announced that its new 65,000 sqft Abildager facility in Copenhagen has received official Manufacturing and Importation Authorisation from the Danish Medicines Agency.
This authorisation marks a significant milestone in KLIFO’s continued growth and its commitment to delivering innovative, flexible and sustainable CTS solutions for the pharmaceutical and biotech industries.
The purpose-built facility is designed to meet the increasing demand for advanced clinical trial supply services and includes the following:
- Significantly expanded capacity to support small-scale studies through to global Phase III and post-marketing trials
- Comprehensive temperature management from controlled room temperature to -80°C for storage, primary and secondary packaging and distribution
- Low-light capabilities for light-sensitive products.
"Approval of our new facility represents a major step forward for KLIFO and the site has already attracted significant interest from Nordic and international clients, reinforcing Copenhagen’s position as a leading life science hub in Europe," said René Pedersen, CEO, KLIFO.
"We can now offer even greater capacity to meet complex clinical trial supply chain needs globally while maintaining our focus on quality, compliance and flexibility."
The new facility, combined with KLIFO’s experienced team, growing international reach and compliance with global requirements, means that KLIFO can accelerate project setup, reduce turnaround times and minimise clinical supply chain issues.